| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Interleukin-17B; IL-17B; Cytokine CX1; Cytokine-like protein ZCYTO7; Neuronal interleukin-17-related factor; Il17b; Nirf, Zcyto7 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived human M Cadherin/CDH15 recombinant protein (Position: L61-D742). |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-M Cadherin/CDH15 Antibody Picoband® is an antibody for CDH15 detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Human,Mouse,Rat. Commonly used in WB, IHC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: CDH15 (interleukin 17B); UniProt: P55291
- Antibody format: Rabbit, Polyclonal, Rabbit IgG
- Molecular weight: 130 kDa
- Applications: WB, IHC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-M Cadherin/CDH15 Antibody Picoband® catalog # A10888-1.
Biological background
Biological context: Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1. .
Expression and localization notes: cellular localization: Secreted., tissue context: Expressed in adult pancreas, small intestine, stomach, spinal cord and testis. Less pronounced expression in prostate, colon mucosal lining, and ovary..
Common research applications
- Western blotting (WB): Compare CDH15 levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of CDH15 in tissue sections, considering fixation and antigen retrieval effects.
- Flow cytometry: Quantify CDH15-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Background: Cadherin-15 is a protein that in humans is encoded by the CDH15 gene. This gene is a member of the cadherin superfamily of genes, encoding calcium-dependent intercellular adhesion glycoproteins. Cadherins consist of an extracellular domain containing 5 cadherin domains, a transmembrane region, and a conserved cytoplasmic domain. Transcripts from this particular cadherin are expressed in myoblasts and upregulated in myotubule-forming cells. The protein is thought to be essential for the control of morphogenetic processes, specifically myogenesis, and may provide a trigger for terminal muscle cell differentiation.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Secreted.
- Tissue details: Expressed in adult pancreas, small intestine, stomach, spinal cord and testis. Less pronounced expression in prostate, colon mucosal lining, and ovary.
- Research category: Cytokines,Immunology,Innate Immunity,Interleukins
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.